{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:29:20Z","timestamp":1787981360744,"version":"build-2784847793"},"reference-count":50,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Annexin A2 (ANXA2) promotes myeloma cell growth, reduces apoptosis in myeloma cell lines, and increases osteoclast formation. ANXA2 has been described in small cohorts of samples as expressed by myeloma cells and cells of the BM microenvironment. To investigate its clinical role, we assessed 1148 samples including independent cohorts of 332 and 701 CD138-purified myeloma cell samples from previously untreated patients together with clinical prognostic factors, chromosomal aberrations, and gene expression\u2013based high-risk scores, along with expression of ANXA2 in whole BM samples, stromal cells, osteoblasts, osteoclasts, and BM sera. ANXA2 is expressed in all normal and malignant plasma cell samples. Higher ANXA2 expression in myeloma cells is associated with significantly inferior event-free and overall survival independently of conventional prognostic factors and is associated with gene expression\u2013determined high risk and high proliferation. Within the BM, all cell populations, including osteoblasts, osteoclasts, and stromal cells, express ANXA2. ANXA2 expression is increased significantly in myelomatous versus normal BM serum. ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients.<\/jats:p>","DOI":"10.1182\/blood-2012-03-415588","type":"journal-article","created":{"date-parts":[[2012,6,17]],"date-time":"2012-06-17T21:30:22Z","timestamp":1339968622000},"page":"1087-1094","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":108,"title":["Clinical and prognostic role of annexin A2 in multiple myeloma"],"prefix":"10.1182","volume":"120","author":[{"given":"Anja","family":"Seckinger","sequence":"first","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mei\u03b2ner","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Montpellier, Institute for Research in Biotherapy, H\u00f4pital Saint-Eloi, Montpellier, France;"},{"name":"Inserm U1040, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Depeweg","sequence":"additional","affiliation":[{"name":"Orthop\u00e4dische Klinik, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hose","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Klinik und Poliklinik f\u00fcr Unfallchirurgie, Universit\u00e4tsklinikum Gie\u03b2en und Marburg GmbH, Justus-Liebig-Universit\u00e4t Gie\u03b2en, Gie\u03b2en, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"R\u00e8me","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Montpellier, Institute for Research in Biotherapy, H\u00f4pital Saint-Eloi, Montpellier, France;"},{"name":"Inserm U1040, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"R\u00f6sen-Wolff","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Kinder und Jugendmedizin, Universit\u00e4tsklinikum Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Humangenetik, Universit\u00e4t Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Schnettler","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Unfallchirurgie, Universit\u00e4tsklinikum Gie\u03b2en und Marburg GmbH, Justus-Liebig-Universit\u00e4t Gie\u03b2en, Gie\u03b2en, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Ewerbeck","sequence":"additional","affiliation":[{"name":"Orthop\u00e4dische Klinik, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Montpellier, Institute for Research in Biotherapy, H\u00f4pital Saint-Eloi, Montpellier, France;"},{"name":"Inserm U1040, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111808450533000_B1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111808450533000_B2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","article-title":"Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.","volume":"135","author":"Barlogie","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111808450533000_B3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111808450533000_B4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report.","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"2019111808450533000_B5","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome.","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111808450533000_B6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","article-title":"Induction of angiogenesis by normal and malignant plasma cells.","volume":"114","author":"Hose","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111808450533000_B7","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"},{"issue":"44","key":"2019111808450533000_B8","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/onc.2009.257","article-title":"Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.","volume":"28","author":"Seckinger","year":"2009","journal-title":"Oncogene"},{"issue":"1","key":"2019111808450533000_B9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2009.006411","article-title":"Thymosin beta4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.","volume":"95","author":"Caers","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2019111808450533000_B10","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma.","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"26","key":"2019111808450533000_B11","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma.","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808450533000_B12","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1182\/blood-2006-08-043232","article-title":"Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.","volume":"109","author":"Mahtouk","year":"2007","journal-title":"Blood"},{"issue":"21","key":"2019111808450533000_B13","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1038\/sj.onc.1208536","article-title":"Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.","volume":"24","author":"Mahtouk","year":"2005","journal-title":"Oncogene"},{"key":"2019111808450533000_B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-540-85772-3_3","article-title":"Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.","volume":"183","author":"Klein","year":"2011","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"2019111808450533000_B15","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2003-02-0402","article-title":"Identification of genes modulated in multiple myeloma using genetically identical twin samples.","volume":"103","author":"Munshi","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111808450533000_B16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12185-009-0356-8","article-title":"Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma.","volume":"90","author":"Bao","year":"2009","journal-title":"Int J Hematol"},{"issue":"41","key":"2019111808450533000_B17","doi-asserted-by":"crossref","first-page":"30542","DOI":"10.1074\/jbc.M607072200","article-title":"Cloning and characterization of the annexin II receptor on human marrow stromal cells.","volume":"281","author":"Lu","year":"2006","journal-title":"J Biol Chem"},{"issue":"8","key":"2019111808450533000_B18","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2011-11-393348","article-title":"Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment.","volume":"119","author":"D'Souza","year":"2012","journal-title":"Blood"},{"issue":"35","key":"2019111808450533000_B19","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.2174\/138161207782794167","article-title":"The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.","volume":"13","author":"Sharma","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2019111808450533000_B20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1172\/JCI19684","article-title":"Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo.","volume":"113","author":"Ling","year":"2004","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111808450533000_B21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1242\/jcs.00909","article-title":"The role of annexin 2 in osteoblastic mineralization.","volume":"117","author":"Gillette","year":"2004","journal-title":"J Cell Sci"},{"issue":"11","key":"2019111808450533000_B22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1172\/JCI6374","article-title":"Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures.","volume":"103","author":"Menaa","year":"1999","journal-title":"J Clin Invest"},{"issue":"46","key":"2019111808450533000_B23","doi-asserted-by":"crossref","first-page":"28696","DOI":"10.1016\/S0021-9258(19)61961-7","article-title":"Cloning and identification of annexin II as an autocrine\/paracrine factor that increases osteoclast formation and bone resorption.","volume":"269","author":"Takahashi","year":"1994","journal-title":"J Biol Chem"},{"issue":"7","key":"2019111808450533000_B24","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1359\/JBMR.050207","article-title":"Annexin II stimulates RANKL expression through MAPK.","volume":"20","author":"Li","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"29","key":"2019111808450533000_B25","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome.","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111808450533000_B26","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"2019111808450533000_B27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma.","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"issue":"15","key":"2019111808450533000_B28","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808450533000_B29","first-page":"300","article-title":"Staging and kinetics of multiple myeloma.","volume":"13","author":"Durie","year":"1986","journal-title":"Semin Oncol"},{"issue":"5","key":"2019111808450533000_B30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111808450533000_B31","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"2019111808450533000_B32","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","article-title":"Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy.","volume":"116","author":"van Rhee","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111808450533000_B33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111808450533000_B34","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","article-title":"Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.","volume":"83","author":"Zhang","year":"1994","journal-title":"Blood"},{"issue":"5","key":"2019111808450533000_B35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2019111808450533000_B36","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.yexcr.2010.03.013","article-title":"Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.","volume":"316","author":"Fuhler","year":"2010","journal-title":"Exp Cell Res"},{"issue":"11","key":"2019111808450533000_B37","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.exphem.2005.07.003","article-title":"Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood.","volume":"33","author":"Wagner","year":"2005","journal-title":"Exp Hematol"},{"issue":"2","key":"2019111808450533000_B38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","article-title":"Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma.","volume":"19","author":"Wuilleme","year":"2005","journal-title":"Leukemia"},{"key":"2019111808450533000_B39","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1198\/016214504000000683","article-title":"A model-based background adjustment for oligonucleotide expression arrays.","volume":"99","author":"Wu","year":"2004","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2019111808450533000_B40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods.","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"2019111808450533000_B41","first-page":"108","article-title":"PANP\u2013a new method of gene detection on oligonucleotide expression arrays.","author":"Warren","year":"2007"},{"key":"2019111808450533000_B42","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments.","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"2019111808450533000_B43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B"},{"issue":"10","key":"2019111808450533000_B44","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics.","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"issue":"26","key":"2019111808450533000_B45","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111808450533000_B46","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","article-title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.","volume":"113","author":"Sprynski","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111808450533000_B47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/path.1935","article-title":"Tenascin C and annexin II expression in the process of pancreatic carcinogenesis.","volume":"208","author":"Esposito","year":"2006","journal-title":"J Pathol"},{"issue":"2","key":"2019111808450533000_B48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.yexmp.2006.03.003","article-title":"Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression.","volume":"81","author":"Sharma","year":"2006","journal-title":"Exp Mol Pathol"},{"issue":"10","key":"2019111808450533000_B49","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/sj.onc.1206196","article-title":"Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration.","volume":"22","author":"Liu","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"2019111808450533000_B50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jcb.21835","article-title":"Annexin II\/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer.","volume":"105","author":"Shiozawa","year":"2008","journal-title":"J Cell Biochem"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/1087\/1361708\/zh803112001087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/1087\/1361708\/zh803112001087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:05:03Z","timestamp":1714057503000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/5\/1087\/30248\/Clinical-and-prognostic-role-of-annexin-A2-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,2]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,8,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-415588","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,2]]}}}